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Abstract
Background and purpose: Placebo response rates in clinical trials vary considerably and are
observed frequently. For new drugs it can be difficult to prove effectiveness superior to placebo. It
is unclear what contributes to improvement in the placebo groups. We wanted to clarify, what
elements of clinical trials determine placebo variability.
Methods: We analysed a representative sample of 141 published long-term trials (randomized,
double-blind, placebo-controlled; duration > 12 weeks) to find out what study characteristics
predict placebo response rates in various diseases. Correlational and regression analyses with study
characteristics and placebo response rates were carried out.
Results: We found a high and significant correlation between placebo and treatment response rate
across diseases (r = .78; p < .001). A multiple regression model explained 79% of the variance in
placebo variability (F = 59.7; p < 0.0001). Significant predictors are, among others, the duration of
the study (beta = .31), the quality of the study (beta = .18), the fact whether a study is a prevention
trial (beta = .44), whether dropouts have been documented (beta = -.20), or whether additional
treatments have been documented (beta = -.17). Healing rates with placebo are lower in the
following diagnoses; neoplasms (beta = -.21), nervous diseases (beta = -.10), substance abuse (beta
= -.14). Without prevention trials the amount of variance explained is 42%.
Conclusion: Medication response rates and placebo response rates in clinical trials are highly
correlated. Trial characteristics can explain some portion of the variance in placebo healing rates
in RCTs. Placebo response in trials is only partially due to methodological artefacts and only
partially dependent on the diagnoses treated.
Background
Randomized controlled clinical trials (RCTs) usually
employ a placebo control group to control for non-spe-
cific effects of therapy [1]. These effects comprise, among
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others, statistical regression to the mean, measurement
artifacts, the natural course of diseases [2-4]. and true
healing or improvement due to psychological or non-spe-
cific factors of therapy [5,6]. Thus, placebo response rates
in clinical trials are always a mix of what has been termed
true and false placebo effect [7]. True placebo effects have
recently been defined as therapeutic effects due to the
meaning of an intervention for a patient [8]. Some argue
against the usage of the term "placebo effect" for such pos-
itive non-specific treatment effects, and observe that it is
not possible to determine true placebo response rates in
controlled clinical trials, since a natural history control
group is lacking [9]. An analysis of three-armed trials with
a natural-history control group in addition to treatment
and placebo groups found no significant effect different
from natural history for dichotomous outcomes, but a sig-
nificant effect size of d = -.28 for continuos measures,
which reflects mostly the placebo effect in pain [10]. This
latter study, however, excluded a lot of high quality evi-
dence from non-clinical, experimental studies, from non-
pharmacological studies, from the psychological literature
and older trials which were not randomized but are still
very suggestive of clinical effects of placebos. If that mate-
rial is also taken into account it seems difficult to dismiss
a placebo effect in clinical trials outright [11]. A recent re-
analysis of these data classifying studies into those that
tried to maximize placebo effects and into trials that used
placebo only as a control procedure found a large effect
size of d = .95 for studies maximizing placebo effects,
which was significantly different from studies using pla-
cebo as control (d = .15) [12]. It seems worthwhile, there-
fore, to try to understand what elements placebo response
rates in randomized, placebo-controlled clinical trials
(RCTs) are comprised of.
Although it would be ideal to launch a series of disman-
tling studies within the context of clinical trials to disen-
tangle components of placebo response rates in RCTs, this
is difficult. While in an experimental context many efforts
have been presented recently, within a clinical context
researchers, with a few exceptions [13,14]., seem reluctant
to pursue the issue. A possible, albeit less reliable, route is
the indirect study through secondary analysis of pub-
lished trials. By using a non-selected sample of RCTs and
correlating formal and informal study characteristics with
the placebo response rate in these trials we tried to under-
stand which characteristics of studies contribute to pla-
cebo response rates in RCTs.
In a previous secondary analysis of 26 RCTs with treat-
ment duration of more than 12 weeks we found a signifi-
cant correlation of r = .59 between placebo response rate
and response rate in treatment groups [15]. Using a simi-
lar approach, Kirsch and Sapirstein [16] found an even
higher correlation between treatment and placebo groups
in trials of antidepressants (r = .90). When comparing
these results with psychotherapy studies which used wait-
list controls they estimated the specific treatment effect in
those antidepressant trials to be 25% of the whole treat-
ment effect. A more recent analysis of unpublished FDA
licensing data of new antidepressant drugs, selective sero-
tonin re-uptake inhibitors, corroborates these findings
showing that 82% of the drug effect is duplicated by pla-
cebo, although the study arms are not significantly corre-
lated [17]. Since the data of these study are from licensing
studies which are proprietary and have not been subjected
to peer review, it is difficult to know what to make of this
information.
We decided to replicate and enlarge these findings by con-
ducting another secondary analysis on a larger set of stud-
ies with a more heterogeneous set of diseases. Placebo
response rates in RCTs might vary as a function of the dis-
ease studied, due to methodological artifacts because of
low methodological study quality, as a function of time or
due to other characteristics of a study. Thus, we retrieved
a sample of unselected long-term trials. We coded several
study characteristics and correlated them with the placebo
response rate. We also operationalized study quality to
find out whether placebo response rate is partially an arti-
fact due to variation in quality. Our question was: Is the
placebo response rate in RCTs dependent on time, study
quality or other formal and informal study characteristics?
In order to answer this question we conducted a system-
atic secondary analysis of published trial data.
Methods
Literature search and trial inclusion criteria
We searched the medical literature from 1992 to 1997
(MEDLINE, Cochrane Library) in order to find high qual-
ity long-term clinical trials. We also used existing meta-
analyses in order to locate appropriate studies. Search
terms were "placebo*", "double-blind*", "RCT*", "meta-
analysis", "long*", "*studies", "treatment outcome".
These search terms were combined with different strate-
gies in order to optimize the results. We also handtracked
the reference lists of existing studies and meta-analyses.
Furthermore, we handsearched volume 1997 of main
stream journals (Lancet, New England Journal of Medi-
cine, British Medical Journal, Journal of the American
Medical Association) as well as other leading medical
journals. We also screened Journal Watch, Newsletter of
the New England Journal of medicine, and AIDS Clinical
Care.
Criteria for exclusion and inclusion of trials were formu-
lated in a study protocol in advance.
All studies had to:BMC Medical Research Methodology 2005, 5:26 http://www.biomedcentral.com/1471-2288/5/26
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1 have a double blind placebo controlled randomized
design
2 treat ill adults
3 provide a treatment of at least 12 weeks' duration
4 deal with a medical intervention with placebo control
group
5 give sufficient information for to have outcome rates
calculated for both groups
6 cover the period from 1992 to 1997.
Data extraction
All data were extracted from the report of each trial with
the use of a pretested form and entered into a spreadsheet.
Formal characteristics were coded: (1) disease treated
(ICD-10 diagnosis according to the first and second level);
(2) duration of study; (3) is it a multi-center study (4)
attrition rate (number of drop-outs in each group); (5) is
the statistical evaluation of the study results done accord-
ing to intent-to-treat analysis; (6) rating of study quality;
(7) 'improvement' = response rate with placebo and med-
ical treatment in a manner similar to [18] (i.e. % patients
improved according to main outcome parameter men-
tioned in the study), or alternatively, in prevention trials,
the number of patients (%) without event (e.g., cardiac)
or worsening of the condition being under investigation
(e.g., dementia);
Quality rating
The rating of study quality is notoriously difficult [19].
Although the Jadad-score seems to be accepted since
empirical validation studies exist [20-22], recent data also
cast doubt on its usefulness [23]. Therefore, we followed
recommendations to use a checklist adapted to the study
question [19]. Our quality rating based on the one pro-
posed by Detsky [24] and the Cochrane criteria [25] com-
prised the following items:
1. Description of inclusion and exclusion criteria?
2. Randomisation
3. Allocation concealment
4. Documentation of undesired events
5. Double-blinding of doctor, patient, and evaluator
6. Concomitant treatments
7. Description of statistical methods
8. Predefinition of outcome criteria
9. Documentation of patients lost to follow-up
Items 1, 4, 7-9 were answered in a yes-no format, items 2,
3, 5 and 6 were answered as "yes, and adequate", "yes,
only mentioned", "no".
The coding of study quality was conducted by 2 of the
authors with a subset of 20 studies rated jointly. A coding
manual defined how to code for different aspects of study
quality. The calculation of inter-rater reliability as intra-
class correlation coefficient [26,27] showed sufficient
consistency (r = .77); the widely used coefficient kappa
was not applicable in our case due to the structure of the
data matrix.
Additional questionnaire information
Research on placebo effects normally starts from the pre-
sumption that placebo effects are due to instructions and
contexts of the study, which induce expectations and
other cognitions in patients as well as in physicians. In
turn, these expectations give rise to biological processes
and physical changes.
To test this hypothesis we constructed a questionnaire
asking for additional information (e.g., amount of time
spent with patients, amount of effort invested in the trial,
indications of unblinding, expectations during the study).
Our question was: is there a correlation between surrogate
measures for expectancies of the principal investigators
and the response rates.
For a subset of studies with recent publication dates we
contacted the original researchers to elicit more informa-
tion about study characteristics which are not normally
reported in publications. We faxed or e-mailed a standard-
ized questionnaire to those investigators who had
responded positively to initial telephone requests. This
questionnaire asked for informal addditional informa-
tion. Four questions referred to organisational aspects of
the trial (who initiated and financed the study?). Seven
questions referred to possible aspects of methodological
quality like unblinding, four questions were about time
and intensity of contacts between the nursing staff,
researchers and patients, and eleven questions referred to
the attitude of the principal investigators towards the
study, the study result and their expectations during the
study. The questionnaire was originally in German, trans-
lated into English by a native speaker, who was fluent in
German, and retranslated by a German native speaker flu-
ent in English.BMC Medical Research Methodology 2005, 5:26 http://www.biomedcentral.com/1471-2288/5/26
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Statistical evaluation
Diagnosis according to ICD 10 classification (first 2
descriptive levels) was converted into dummy variables
(1,0-coding). All entered data were checked twice for
plausibility and correctness by two independent persons.
Descriptive information was taken from the study reports.
The rating of study quality was added to a single
unweighted quality score, after inspecting correlational
patterns on single-item level. Improvement rate with
treatment and placebo was defined as proportion of
improved patients in relation to all patients treated within
this group. Normally, this is reported in the original pub-
lications, or else it was calculated. Studies with more than
two study arms were treated as two different studies, if
separate placebo groups were employed. In dose finding
studies with more than one treatment arm we always used
the treatment group with the highest efficacy.
Data of the investigators' questionnaire was used on a sin-
gle item level. Additionally, we formed different indices
out of the items of the questionnaire which were meant to
reflect "high involvement" (e.g. time, personal effort),
high expectation or high importance of a study by group-
ing items according to their topic.
We calculated first order correlations of formal and infor-
mal study characteristics with placebo response rates.
Based on these results and on our previous finding we for-
mulated parsimonious regression models weighted by
study size (n-3) as recommended in [28] to clarify which
variables contribute to placebo response rates. In order to
minimize capitalization of chance we only used theoreti-
cally interesting variables, those with significant first order
correlations, and those that seemed promising after a first
stepwise hierarchical model. In a second step we took out
all non-significant predictors and entered all variables in
the hypothesized sequence of importance in a forced
regression model. Residuals were checked for possible
non-linearity.
Results
Our search strategy produced after initial screening for
sensitivity and specificity in its definite version 375 stud-
ies. The abstracts were screened for inclusion criteria.
These were fulfilled by 141 studies. Figure 1 gives details
about inclusion of trials.
Table 1 gives the number of studies according to ICD
categories.
Since in some studies there were multiple arms of treat-
ment and control groups the basis for the statistical calcu-
lations is N = 153 independent combinations of placebo
and treatment effects. Table 2 gives the significant first
order correlations between the relevant variables of study
characteristics.
Improvement rates in placebo groups were significantly
correlated with improvement rates in the treatment
groups (r = .78; Fig. 2), and with duration of study (r =
.41). If only the subset of 97 therapeutic trials excluding
prevention studies are analysed, the correlation remains
significant (r = .61). Placebo improvement rates are lower
in trials of behavioral disorders due to psychotropic sub-
stances (r = -.19; recall that disease categories were
dummy coded as 1: belonging to category; 0: not belong-
ing to category), in dementia (r = -.16) and anti-epileptic
trials (r = -.30). They are higher in prevention studies (r =
.59) and trials of ischemic and other forms of heart dis-
ease (r = .45). They are unrelated to other forms of diag-
nosis and most notably unrelated to the quality of the
trials, on single item level as well as on the index level,
when considered as zero-order correlations. Nearly the
same patterns of correlations can be found for the
improvement rates with treatment.
We checked in a regression model for the predictive power
of the combined variables. A significant regression model
emerged that was able to predict nearly 80% of the varia-
bility of response in the placebo group (adjusted R2 =
.794; F 10/142 = 59,74; p < 0.0001). This is presented in
table 3. Main predictors were from two categories: meth-
odological and diagnostic. Placebo response rates were
larger for studies with longer study duration (beta = 0.31),
for prevention trials (beta = 0.44), for multicentre trials
(beta = 0.13) and for studies with better methodological
quality (beta = 0.18). The questions whether dropouts
(beta = -0.17) and additional treatments (beta = -.21)
were described, were the important methodological varia-
bles. Therapeutic effects in placebo groups were smaller
for trials of antitumor agents (beta = -0.21), studies in
dementia (beta = -0.12), in substance withdrawal studies
(beta = -0.14) and in studies of nervous diseases, mainly
anti-epileptic trials (beta = -0.10).
Table 4 presents a subsidiary analysis for those 97 studies,
which were not prevention trials. This regression model
was also highly significant and explained 42% of the var-
iance in placebo variability (adjusted R2 = .426; F 5/91 =
15.22; p < 0.0001). Main predictors in this model were
five diagnostic categories, with studies on substance with-
drawal (beta = -0.31) and on nervous diseases/dementia
(beta = -.0.20) showing lower placebo response rates, and
studies in affective disorders, i.e. antidepressant and anxi-
olytic trials, (beta = 0.37), studies in digestive diseases,
mostly inflammatory bowel conditions (beta = 0.29) and
studies in urogenital diseases (beta = 0.16) showing better
placebo treatment rates. Most notably, methodological
quality did not contribute to the model.BMC Medical Research Methodology 2005, 5:26 http://www.biomedcentral.com/1471-2288/5/26
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Flowchart of study inclusion Figure 1
Flowchart of study inclusion.




Publications < 1992 
N = 6 
p
EXCLUSION: 
Duration of treatment < 12 weeks
N = 87 
p
EXCLUSION:  
Design not double-blind, cross-over, no placebo, no 
randomization, only placebo wash-out phase 
N = 66 
p
EXCLUSION:  
Population (Healthy volunteers, Age < 18 years)
N = 23 
p
EXCLUSION: 
Language (Russian, Finnish) or not available
N = 6 
p
EXCLUSION: 
Data (no effect parameter or information insufficient for 
calculation of response rates, abstracts, letters, phase 1 or 
phase 2 studies) 
N = 46 
p
 Inclusion: N = 141 Studies BMC Medical Research Methodology 2005, 5:26 http://www.biomedcentral.com/1471-2288/5/26
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Table 1: Number of studies according to ICD categories
ICD-10 Category Disease category No of studies
A, B Infectious and parasitical diseases 4
C Neoplasms (Tumours) 5
E Endocrine, nutritional and metabolic diseases 8
Psychological and behavioural disorders
F0 Organical, including symptomatical psychological disorders 4
F1 Psychol. and behav. disorders due to psychotropic substance abuse 22
F3 Affective disorders 13
F4 Neurotic, stress and somatoform disorders 12
F5 Behav. abnormalities with somatic disorders 5
F6 Personality and behavioural disorders 1
F8 Developmental disorders 1
G Nervous diseases 14
Diseases of circulatory system
I10/11 High blood pressure 4
I20-I52 Ischemic and other forms of heart disease 21
I6/7 Cerebrovascular and other peripheral vascular diseases 2
J4 Pulmonary diseases 2
K Digestive diseases 6
L Diseases of the skin 1
M Diseases of the muscular skeletal system and of connective tissue 9
N Diseases of the urogenital system 3
T8 Trauma, intoxications and other consequences of extraneous causes 2
Y4 Extraneous causes of morbidity and mortality 2
Number of all included studies N = 141
Table 2: First order correlations between study characteristics (Pearson), N = 153
%_T %_P DUR. DIA_E DIA_F0 DIA_F1 DIA_F4 DIA_G DIA_ I1 DIA_ I2 PREV INDEXQR
%_T 1,00 ,78*** ,29*** ,01 -,14 -,33*** ,01 -,31*** ,14 ,37*** ,49*** ,03
%_P 1,00 ,41*** ,07 -,16* -,19* -,11 -,30*** ,12 ,45*** ,59*** ,08
DUR. 1,00 ,26** -,08 -,18* -,18* -,16 ,41*** ,25** ,40*** ,12
DIA_E 1,00 -,04 -,11 -,07 -,07 -,04 -,10 ,25** -,15
DIA_F0 1,00 -,07 -,05 -,05 -,03 -,07 ,05 -,05
DIA_F1 1,00 -,13 -,14 -,08 -,19* -,27** -,03
DIA_F4 1,00 -,09 -,05 -,12 -,22** -,02
DIA_G 1,00 -,06 -,13 -,24** -,06
DIA_I1 1,00 -,08 ,01 ,05
DIA_I2 1,00 ,54*** ,14
PREV 1,00 ,11
INDEXQR 1,00
*) p < .05 **) p < .01 ***) p < .001
Legend: %_T Percent of patients improved with treatment
%_P Percent of patients improved with placebo
DUR. Duration of study in months
DIA_E: Diabetes, other diseases of secretory glands and metabolism
DIA_F0: Dementia
DIA_F1: Behavioural disorders due to psychotropic substances
DIA_F4: Panic disorders
DIA_G: Epilepsy
DIA_I1: High blood pressure
DIA_I2: Ischemic and other forms of heart disease
PREV. Studies with preventive targets
INDEXQR Quality indexBMC Medical Research Methodology 2005, 5:26 http://www.biomedcentral.com/1471-2288/5/26
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Additional questionnaire information
Principal investigators of 57 recently published studies
were asked for retrospective additional information. 50 of
those answered our request (87%), and 44 supplied suffi-
cient data. There is only one significant first order correla-
tion out of all items. Apart from the correlation between
placebo and treatment response rates there is no signifi-
cant and substantial correlation except for chance fluctua-
tions. But we found evidence for unblinding in 30% of the
44 responses.
Monte Carlo simulation
One of the possible sources of the correlation between
placebo and verum effect might be publication bias, espe-
cially when there is no significant difference between the
placebo and verum condition. In order to explore this
potential source of the correlation we simulated the situa-
tion of publication bias by assuming that only trials were
published where the differential effect had a chance prob-
ability of p < 0.01
The simulation parameters used were:
a) mean effect size of the placebo: ESp
b) mean effect size of the verum: ESv
c) Number of subject in a trial: Nss
d) Number of experiments per effect: Nexp
If no publication bias is assumed, there is no correlation
between verum and placebo effect sizes. However, there
were significant correlations when a publication bias was
introduced. This was the case for each reasonable choice
of simulation parameters. In Figure 3 a scatterplot for
published placebo and verum effect sizes are given for a
typical choice of simulation parameters. The correlation
obtained is r = 0.63, close to the true correlation. In other
words publication bias could, in principle, explain nearly
all variance, assuming that all non-significant studies are
suppressed. It should be noted, however, that the file-
drawer for this particular simulation contains 86% of all
experimental results. It is improbable that so many trials
would remain unpublished.
Discussion
This secondary analysis was motivated by the attempt to
understand what influences placebo response rates in
RCTs. We found a rather strong correlation between
improvement rates with placebo and treatment of r = .78,
which explains roughly 60% of the variance. The magni-
tude of the correlation drops somewhat to r = .61, explain-
ing 37% of the variance, if only therapeutic trials are
considered. This result is in concordance with our own
and other previous findings [15,17,29]. It is incidentally
backed by an early result reported by Evans [30]. Although
Evans' finding has been explained as a result of the skewed
distribution of the underlying binary data [31], this expla-
nation does not apply to our data, which followed a Gaus-
sian distribution.
This high correlation should not come as a surprise, as in
clinical trials a certain basic effect, thought to be covered
by the placebo control group, is compared with this same
basic effect plus some specific element of pharmacologic
intervention. That is, effects in clinical trials are bound to
be correlated. Indeed, if there were no intervention effects
at all we would have a perfect correlation of r = 1.0. The
fact that the correlation is not perfect is a sign that treat-
ment and control groups behave differently. The fact that
the correlation is so high and in fact explains 60% of the
variance is a sign that the commonalities of factors in
groups within trials is greater than their difference. In
other words, non-specific treatment effects are more
important than the specific ones. Thus we have once more
corroborated a now growing body of evidence about the
importance of non-specific treatment effects [14,32].
Natural history or cohort effects might be an explanation
for the high correlation between treatment and placebo
response. The correlations found in our study are
suggestive of an overall small to moderate treatment effect
reflecting in an imperfect correlation. Although a cohort
effect is a possible explanation, we would like to point out
that durations of trials are normally chosen according to
the disease studied and to cover a time period which cap-
tures a relevant portion of natural fluctuation. For
Scatterplot of response rate with drug and placebo for all  studies Figure 2
Scatterplot of response rate with drug and placebo for all 
studiesBMC Medical Research Methodology 2005, 5:26 http://www.biomedcentral.com/1471-2288/5/26
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instance, depression maintenance trials are normally
conducted over a time span long enough to make a recur-
rence in untreated patients likely, or dementia trials cover
a period, where a progression of the disease is to be
expected. Thus, natural history is partly covered by the dif-
fering trial durations of the studies analyzed. If natural
history were the only factor reflected in the improvement
rates of placebo groups, on average we should expect dete-
riorations or little improvement in placebo groups,
because the diseases studied here are mostly long-term
chronic diseases with little self-limiting tendencies. Across
all studies, diseases and trial durations of a heterogeneous
set of studies we should expect that cohort effects average
out and the correlation between treatment and placebo
improvement should tend towards zero [31]. In fact, our
simulation produces a zero-correlation for many different
scenarios of study outcomes, confirming this intuitive rea-
soning. Thus, there seem to be non-specific elements of
treatment at work here that reflect in improvement rates
in placebo groups which are grossly comparable to those
in the treatment groups.
What is important from a differential point of view is,
whether these non-specific elements of treatments, or the
variability of responses in the placebo groups, can be fur-
ther elucidated. Our regression analysis shows that a series
of formal characteristics is responsible for this variability
of therapeutic responses in placebo groups. The fact that
this analysis can explain nearly 80% of the variance is a
support for the hypothesis that a large part of those non-
specific effects in randomised placebo controlled trials is
due to formal characteristics. The effect in placebo control
groups is higher in studies with a longer duration and in
prevention trials. Prevention trials are normally also
longer in duration. In fact this effect of duration of trial
vanishes when prevention trials are taken out of the anal-
ysis (compare Tables 3 and 4). This strong effect of pre-
vention trials is worth considering. It means that in such
trials the event rate in the control group is smaller, i.e. the
placebo healing rate higher, than in comparable curative
trials. It may be the psychological focus on preventing an
event that triggers effects different from placebos in cura-
tive trials. It may simply be the fact that in prevention tri-
als medications, and placebos, are given for a very long
time, sometimes over years, and hence expectations for
maintainance of a comparatively healthy state are contin-
uously reinforced. Or it may be easier to harness expecta-
tions for maintaining a state of comparative well-being
than to use them for getting well again. This effect of pre-
Table 3: Regression model predicting variability in response rates in placebo groups of clinical trials; n = 153 studies/comparisons; 
formal and diagnostic variables (ICD coding)
Beta t (DFs = 142) p-value
Constant 2.07 0.04
Duration in months 0.31 6.17 <0.000001
Multicenter trial 0.13 3.04 0.003
Quality Index 0.18 3.44 0.0008
Neoplasms (C) -0.21 -5.48 <0.000001
Organical psychological disorders (F0) -0.12 -3.24 0.001
Disorders due to substance abuse (F1) -0.14 -2.97 0.003
Nervous diseases (G) -0.10 -2.55 0.01
Prevention trial 0.44 7.94 <0.000001
Quality rating: Additional treatment described? -0.21 -4.34 0.00003
Quality rating: Dropouts described? -0.16 -3.33 0.001
Table 4: Regression model predicting variability in response rates in placebo groups of clinical trials; n = 97 Studies, with prevention 
trials excluded; formal and diagnostic variables (ICD Coding); italics: different from full model
Beta t (DFs = 91) p-value
Constant 10.3 <0.000001
Disorders due to substance abuse (F1) -0.31 -3.57 0.0006
Affective disorders (F3) 0.37 4.49 0.00002
Nervous diseases (G) -0.20 -2.40 0.018
Digestive diseases (K) 0.29 3.65 0.0004
Diseases of the urigenital system (N) 0.16 2.09 0.039BMC Medical Research Methodology 2005, 5:26 http://www.biomedcentral.com/1471-2288/5/26
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vention trials warrants a deeper scrutiny than can be pro-
vided by a retrospective analysis.
This predictive power of prevention trials is by far the
strongest effect in our data base, which also explains par-
tially the other elements: prevention trials are normally
not only longer, but also larger and require the effort of
many centres. Therefore they are in tendency better
planned and have a slightly better methodology. These
methodological factors disappear, when the analysis is
repeated with prevention trials excluded. It is obvious that
placebo variability is different for different diseases. In the
full data-set trials of anti-tumor agents, of anti-epileptics,
of anti-dementia drugs, and of substance withdrawal con-
tribute to variability by exhibiting smaller placebo effects.
However, this should not blind us to the fact that the beta-
weights, which are correlation coefficients adjusted for the
effects of all other variables, of these diagnostic variables
are rather small. In the reduced data-set, without the
prevention trials, improvement rates in placebo groups
are higher in studies of affective disorders, which com-
prise mainly antidepressant and anxiolytic studies, in
studies of anti-inflammatory agents in bowel diseases and
in studies of urogenital diseases. Improvement rates are
lower for substance withdrawal studies and anti-epilep-
tics. The fact that the regression model in the reduced
data-set explains only 42% of the variance and thus has
approximately only half the explanatory power of the full
set shows that other unknown factors are operative,
besides spontaneous improvement rates in different dis-
eases. Otherwise we would expect a stronger effect of the
diagnostic categories in our regression model.
Our simulation runs brought one other explanatory
option to the fore: publication bias. Under the assump-
tion that only trials are published that prove the signifi-
cance of the treatment over placebo and the non-
significant trials are filed away, simply by this publication
bias alone, a correlation can be obtained which is close to
the one we observed empirically. Thus it is tempting to
assume that the true reason for the high correlation
between treatment and placebo improvement rates is, at
Scatterplot of results of simulation of the effect of publication bias. Simulation parameters were: Esp = 0.5, ESv = 0.51 - 0.60 in  steps of 0.01, Nexp = 50, Nss = 100 Figure 3
Scatterplot of results of simulation of the effect of publication bias. Simulation parameters were: Esp = 0.5, ESv = 0.51 - 0.60 in 
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least partially, publication bias. This points, once more, to
the importance of publishing all evidence, not only posi-
tive studies. However, bearing in mind that the simula-
tion produced a correlation of r = .63 under the
precondition that all non-significant evidence, i.e. 87% of
all evidence remained unpublished, publication bias can-
not account for the whole correlation, but perhaps for a
substantial amount.
Although not quite as obvious, one of the most important
messages of this study is hidden behind what we have not
found:
There is no sizeable effect of methodological quality apart
from the one discussed above which is explained by the
prevention trials. This means that placebo variability in
clinical trials is not only due to methodological artifacts,
as is sometimes suggested [2,3], at least as assessed by our
scale.
Frequently it is proposed that placebo responses are due
to heightened expectations of investigators and subse-
quently patients in trials. Since trials are conducted with
more frequent and more intense contacts between doctors
and patients, the argument would run, patients could
form stronger expectations of improvement, which in
turn could lead to response expectancies, which again
would result in clinical improvement [33]. We could not
test this hypothesis directly. But we did test it indirectly by
asking principal investigators to give information on
study characteristics not normally reported in publica-
tions, like amount of time spent with patients, amount of
effort invested in a trial, importance of the trial for further
funding, expectation of investigator and the like. None of
these indirect operationalizations of heightened expecta-
tion and increased effort on part of the investigators
showed any notable correlation with placebo response
rates.
We found substantial evidence for unblinding of investi-
gators in 30% of 44 trials with additional questionnaire
data. Surprisingly enough, placebo response rate was
uncorrelated  with unblinding. Thus, patients in studies
with indications for investigator unblinding had a higher
improvement rate only in the treatment group, but not in
the placebo group. If investigator opinion was a decisive
factor in the creation of patient expectancies, we would
expect a substantial negative correlation between
unblinding and placebo response rate. Since unblinding
occurred in 30% of the cases, we should have been able to
see such a correlation if it had been present. It is obviously
not an issue. Thus, informal characteristics in studies,
reflecting a higher awareness and a stronger engagement
of investigators and patients in clinical trials, do not seem
to influence the amount of improvement in placebo
groups. We submit that this part of our data is rather weak,
since it is retrospective evidence. Nevertheless, it is a first
empirical data set which could be followed up by prospec-
tive studies.
What other explanations or mechanisms could be respon-
sible for this effect? One idea is well known and posits
that clinical trials are in fact healing rituals with a strong
non-specific effect [33]. The other invokes the new con-
cept of generalized entanglement in systems.
Trials as healing rituals
Treatment effects of mostly pharmacological interven-
tions studied here do have some effect, but the effect is
smaller than those of non-specific effects. It has been
argued that therapeutic effects are meaning effects in gen-
eral, with pharmacological or other medical interventions
adding a plausibility factor that actually triggers this
meaning effect [34]. A meaning effect would be an indi-
vidual healing effect induced by the complex interaction
between an individual, constructing meaning out of his or
her medical situation, the medical system trying to inter-
vene, physiological changes brought about by the inter-
ventions and psychological changes inferred by the
individual and hence altered psychological states. These
states have been documented as altered brain function
[35-40] and hence it is plausible to assume that they can
also affect complex medical conditions.
Such an interpretation could be supported by our data,
since the non-specific elements are by far the more impor-
tant ones, compared with the specific elements of
treatment. Non-specific effects account for nearly 60% of
the variance of all treatment effects. This is true for most
disease categories and across a wide variety of interven-
tions. This alone should be an intriguing result, stimulat-
ing more research effort into mechanisms and processes
of unspecific effects of therapy in general and trials in
particular.
Correlation effects as an instance of generalized
entanglement:
According to a weaker and generalized version of quan-
tum theory [41], applicable to different systems outside
the realm of physics, entanglement, i.e. non-local correla-
tions structurally similar to but factually different from
quantum correlations, would be expected in any system
with a global observable and a local observable that are
complementary and do not commute; in addition they
may have to share a common contextual history (D. Gern-
ert, personal communication). A clinical, blinded trial is
such a system by definition. The global observable is the
blinding of the trial, the local observable is the actual allo-
cation of patients to treatment groups. Global blindingBMC Medical Research Methodology 2005, 5:26 http://www.biomedcentral.com/1471-2288/5/26
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and local definite allocation are complementary notions,
and thus entanglement would be predicted, visible as a
correlation across trials. The common context is given by
the aim and the procedures of the trial. This hypothesis,
which has received some support recently by experimental
data in other areas [42], would have to be investigated fur-
ther by means of direct experimentation. For the time
being this is only a speculative possibility. However,
should it bear out, it would have consequences both for
study methodology and for clinical practice. On the one
hand, it would be expected that medications show differ-
ent, mostly stronger, effects in unblinded contexts, on the
other hand it would follow that data from blinded trials
are biased estimators of real effect sizes.
We would like to add some cautions:
It is difficult to draw firm conclusions about non-specific
effects from two armed-trials [9]. This should be born in
mind, when interpreting our data, since all our evidence
and argument is indirect by default. Our retrospective
questioning of principal investigators may be considered
weak. While we agree that only a few investigators could
be queried and retrospectively gathered evidence is far
from compelling, there is no selection behind our sam-
pling procedure but only temporary sequence. And
among those selected we achieved a high return rate. Thus
we are confident that we have at least given a small part of
the picture reliably, and it goes without saying that this
piece of our evidence can only be a hint for further
research. It should be elucidated in prospective analyses,
whether and how often unblinding is seen and how this
affects outcome rates. It could be documented before
knowledge of outcomes, how strong extra involvement
and enthusiasm of doctors and investigators have been
compared to conventional clinical practice. Until such
prospective evidence is available, we have produced at
least some estimators of trial effects and have not found
convincing evidence for them.
Conclusion
We conclude that the placebo response rate in controlled
clinical trials is not due to methodological artifacts, to dis-
ease history alone or to circumstantial characteristics of
studies, but seems to reflect a genuine improvement,
unless one invokes publication bias for all negative stud-
ies. This improvement accounts for roughly 60% of the
variance of all therapeutic gains across trials.
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